Testosterone Therapy in Men with Hypogonadism
|
|
- Brittney Terry
- 5 years ago
- Views:
Transcription
1 Testosterone Therapy in Men with Hypogonadism (Endocrine Society 2018 Guideline) Ngwe Yin, MD Assistant Clinical Professor of Medicine, UCSF Fresno Medical Education Program
2 Disclosures None
3 Objective At the end of the talk, you will be able to Diagnose androgen deficiency syndromes in men Choose therapeutic options for patient with diagnosed androgen deficiency Monitor during testosterone therapy
4 3 Key Questions Does the patient have hypogonadism? If yes, primary or secondary hypogonadism? Any contraindication to start T therapy?
5 Case 1 44 M was referred for management of hypogonadism Fatigue, mood changes x 6mo Morning total T ng/dl [Immunoassay] ( ng/dl) at a local lab confirmed with 2 nd morning sample 4 biologic children (wife got pregnant without assistance) Exam: BMI 28, no gynecomastia, normal testicular exam
6 Case 1 What is the appropriate next step? 1. Patient has hypogonadism and start testosterone 2. Confirmed that testosterone assay is accurate and reliable Total T measured by LC/MS/MS 479 ( ng/dl), Free T 85 ( pg/ml) Take home point assay does matter!
7 2018 Testosterone guidelines: T assays Emphasize on use of Accurate and reliable assay - equilibrium dialysis or LC/MS/MS Lab certified by CDC or another accuracy based certifying program _Testosterone_Procedures-508.pdf
8 T assays 1. Immunoassay: a great deal of variability at lower ranges, measures above 250 ng/dl, automated, simple to perform, faster turnaround time, sensitivity and interference issues. 2. LC/MS/MS: good sensitivity, accuracy and precision especially in the low range, can measure as low as low 20 ng/dl, high level of complexity. 3. Equilibrium Dialysis: gold standard method for measuring free T, high level of complexity, takes 2 days to perform.
9 T assays (large interassay & interlaboratory variability) Immunoassays LC/MS/MS Equilibrium Dialysis Quest LabCorp St Agnes Total T ng/dl Free T (calculated) yrs pg/ml >69 yrs pg/ml Total T ng/dl Free T (calculated) yrs pg/ml >59 yrs pg/ml Total T ng/dl Free T send out to Quest Total T ng/dl Total T ng/dl Free T (equilibrium ultrafiltration) ng/dl Free T <70 yrs pg/ml >70 yrs pg/ml Free T (equilibrium dialysis) pg/ml
10 Epic order
11 Case 2 39 M is referred for management of hypogonadism No energy, fatigue x 3 years and getting worse recently Lab: Hb 16.9, Hct 48.2%, total T 232 LC/MS/MS ( ng/dl), Prolactin 5.3, SHBG 7 (10-50), free T 48.9 ( pg/ml) Normal libido, no decreased erection Underwent normal puberty, has 3 biologic children (13, 8, 2 years old wife got pregnant without assistance) ROS: snoring, daytime sleepiness Exam: BMI 39, no gynecomastia, well-virilized, normal testicular exam
12 Case 2 Which of the following is false? 1. Patient likely has OSA and get sleep study 2. Patient has hypogonadism and start T replacement 3. Patient has low total T and SHBG likely due to obesity 4. Relative low total T likely improve if patient loses weight
13 Diagnosis 1.1 We recommend diagnosing hypogonadism only in men with symptoms and signs consistent with testosterone deficiency and unequivocally and consistently low serum total T and/or free T concentration (when indicated). 1.2 We recommend against routine screening of men in the general population for hypogonadism.
14 Diagnosis Symptoms and signs consistent with androgen deficiency 2 fasting 8am total T Free T (if suspect altered SHBG) LH & FSH Semen fluid analysis (if fertility issue) Low T, low or normal LH & FSH Secondary hypogonadism Pituitary hormones, Transferrin Saturation, MRI Obesity, Opioid, Anabolic steroid use Low T, high LH & FSH Primary hypogonadism Karyotype (Klinefelter syndrome)
15 Diagnosis Specific symptoms and signs Incomplete or delayed sexual development Loss of axillary and pubic hair Testes <6 ml Suggestive symptoms and signs Reduced sexual drive Decreased spontaneous erection Gynecomastia Nonspecific symptoms and signs Decreased energy, motivation, self-confidence Depressed mood Poor concentration and memory Sleep disturbance Mild unexplained anemia Reduced muscle bulk and strength Increased body fat, BMI Eunuchoidal body proportions Inability to father child, low sperm count Height loss, low trauma fracture, low BMD Hot flashes, sweats
16 Testosterone Transport Total T = Free T + albumin-bound T + SHBG-bound T Bioavailable T = Free T + albumin-bound T Free Androgen Index = T (ECLIA) : SHBG ratio
17 Measure Free T 1. Conditions associated with SHBG (obesity, DM, glucocorticoid, anabolic steroid use, hypothyroidism, acromegaly, nephrotic syndrome, polymorphisms in SHBG genes) 2. Conditions associated with SHBG (aging, HIV, hepatitis, cirrhosis, hyperthyroidism, estrogen, polymorphisms in SHBG genes) 3. Total testosterone in borderline zone of reference range (eg., ng/dl)
18 Case 3 36 M p/w headache, low libido, decreased erection x 4mo, referred for management of hypogonadism 1 biologic child Exam: BMI 24, normal secondary sexual characteristics and testicular exam Morning total T 150 LC/MS/MS ( ng/dl) x 2 LH 2.0 ( miu/ml) FSH 3.0 ( miu/ml)
19 Case 3 Which of the following is next best step? 1. Start testosterone therapy 2. Measure prolactin and pituitary panel 3. Order MRI pituitary w/wo contrast 4. Karyotyping
20 Prolactin 4000 ( ng/dl)
21 Diagnosis 1.3 In men who have hypogonadism, we recommend distinguishing between primary (testicular) and secondary (pituitary hypothalamic) hypogonadism by measuring serum LH and FSH. 1.4 In men with hypogonadism, we suggest further evaluation to identify the etiology of hypothalamic, pituitary, and/or testicular dysfunction.
22 Diagnosis Primary Hypogonadism Secondary Hypogonadism Organic Klinefelter syndrome Hypothalamic/Pituitary tumor Cryptorchidism, Anorchia Iron overload syndromes Chemotherapy Infiltrative disease of hypothalamus/pituitary Testicular irradiation, trauma, torsion, Orchiectomy Idiopathic hypogonadotropic hypogonadism Advanced age Functional Medications (androgen synthesis inhibitors) Hyperprolactinemia ESRD Opioids, anabolic steroid, glucocorticoid Alcohol, marijuana abuse Systemic illness Severe obesity
23 Case 4 44 M with chronic alcohol use p/w gynecomastia, decreased muscle mass x 1 yr Drank heavily until 2 mo ago, currently drink ½ bottle of vodka a week 2 children (age 10 and 7) Exam: +gynecomastia, normal testicular exam Lab: total T 240 ( ), free T 32.4 (35-155), LH & FSH normal, hcg <2, E2 30 (<52), prolactin 6.7 (<18), AST 134, ALT 80 Mammogram was negative
24 Case 4 Next step? 1. Start T therapy 2. Abstinence from EtOH and repeat total T in 3 months Alcohol is known to cause functional secondary hypogonadism Therefore, to repeat testing after abstinence from alcohol Total T improved to 627 ng/dl 6 months of no EtOH Gynecomastia also improves
25 Treatment 2.1 We recommend testosterone therapy in hypogonadal men to induce and maintain secondary sex characteristics and correct symptoms of testosterone deficiency We recommend against T therapy in men planning fertility or in men with breast or prostate Ca, a palpable prostate nodule/induration, PSA >4 ng/ml, PSA >3 ng/ml combined with a high risk of prostate Ca, elevated hematocrit, untreated severe OSA, severe LUTS, uncontrolled HF, MI or stroke within the last 6 months, or thrombophilia.
26 Older men with age-related decline in T concentration 2.4 We suggest against routinely prescribing testosterone therapy to all men 65 years or older with low T. In men 65 years who have symptoms consistent with T deficiency and consistently and unequivocally low morning T, we suggest that clinicians offer testosterone therapy on an individualized basis after explicit discussion of the potential risks and benefits.
27 Treatment Formulation Starting doses Monitoring (measure T) T enanthate or T cypionate T transdermal gel 1%, 1.62%, 2% T transdermal patch T undecanoate LA mg IM every 2 weeks or mg IM weekly mg of 1% mg of 1.62% Midway between injection (IM) 2-8 h following application 1 or 2 patches (2-4 mg) daily 3-12 h after application 750 mg IM, at 750 mg at 4 wk, then 750 mg every 10 wk at the end of dosing interval T pellets mg implanted SC at the end of dosing interval
28 2018 Testosterone guidelines: Monitoring Assess symptoms respond to treatment Assess any adverse effects Serum T (target mid-normal range) Hematocrit (stop if Hct >54%, evaluate OSA) Bone density if osteoporosis Prostate monitoring (shared decision making) Age and age who at increased risk for prostate Ca who choose monitoring At 3 months, each visit At 3 months, dose change, annually Baseline, at 3 months, annually Every 2 years DRE + PSA before initiation At 3-12 months after initiation, then in accordance with prostate Ca screening guidelines
29 Monitoring Urology consultation if Increase in serum PSA >1.4 ng/dl within 12 months of initiating T treatment PSA >4 ng/dl at any time Abnormal DRE Substantial worsening of LUTS (lower urinary tract symptoms)
30 Take home points Recommends making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone deficiency and unequivocally and consistently low serum T concentrations. Recommends the use of accurate assays for the measurement of total and free testosterone and rigorously derived reference ranges for the interpretation of testosterone levels. Recommend confirming the diagnosis by repeating the measurement of morning fasting total T concentrations. In men determined to have androgen deficiency, we recommend additional diagnostic evaluation to ascertain the cause of androgen deficiency. We recommend against starting T therapy in patients who are planning fertility in the near term or have any of a number of specified conditions.
31 References
Hypogonadism 4/27/2018. Male Hypogonadism -- Definition. Epidemiology. Objectives HYPOGONADISM. Men with Hypogonadism. 95% untreated.
Male Hypogonadism -- Definition - Low T, Low Testosterone Hypogonadism -...a clinical syndrome that results from failure of the testes to produce physiological concentrations of testosterone due to pathology
More informationTestosterone Treatment: Myths Vs Reality. Fadi Al-Khayer, M.D, F.A.C.E
Testosterone Treatment: Myths Vs Reality Fadi Al-Khayer, M.D, F.A.C.E The Biological Functions of Testosterone in Men Testosterone is essential to the musculoskeletal and metabolic systems throughout a
More informationGUIDELINES ON. Introduction. G.R. Dohle, S. Arver, C. Bettocchi, S. Kliesch, M. Punab, W. de Ronde
GUIDELINES ON Male Hypogonadism G.R. Dohle, S. Arver,. Bettocchi, S. Kliesch, M. Punab, W. de Ronde Introduction Male hypogonadism is a clinical syndrome caused by androgen deficiency. It may adversely
More informationEvaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients
Evaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients Jeff Unger, MD Director Chino Medical Group Diabetes and Headache Intervention Center Chino, California January 16, 2008
More information6/14/2010. GnRH=Gonadotropin-Releasing Hormone.
Male Androgen Replacement Mitchell Sorsby, MD June 19, 2010. QUESTION # 1 Which of the following is not a symptom associated with low T levels? a) decreased libido b) erectile dysfunction c) depression
More informationRecognizing and Managing Testosterone Deficiency
Recognizing and Managing Testosterone Deficiency J. Bruce Redmon, M.D. Professor Division of Endocrinology Departments of Medicine and Urologic Surgery Disclosure Information I have no financial relationships
More informationOVERVIEW OF PRESENTATION
Thanh D. Hoang, DO, FACP, FACE Division of Endocrinology Department of Internal Medicine WRNMMC 13 Aug 2018 OVERVIEW OF PRESENTATION Take Home Points Definition of Hypogonadism Clinical Manifestations
More informationEAU GUIDELINES ON MALE HYPOGONADISM
EAU GUIDELINES ON MALE HYPOGONADISM (Text update March 2015) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch, M. Punab Introduction Male hypogonadism is a clinical syndrome caused by
More informationAndrogen deficiency. Dr Rakesh Iyer Staff Specialist in Endocrinology Calvary hospital
Androgen deficiency Dr Rakesh Iyer Staff Specialist in Endocrinology Calvary hospital Outline Pathological androgen deficiency - Background, causes, interpretation - Indications for treatment Androgen
More informationLate onset hypogonadism
Late onset hypogonadism Farrukh Javid Male Menopause Clinical AND biochemical syndrome Testosterone levels decline by 0.4-3% per year after the age of 30, as opposed to the more rapid decline that occurs
More informationEAU GUIDELINES ON MALE HYPOGONADISM
EAU GUIDELINES ON MALE HYPOGONADISM (Limited text update March 2017) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch Introduction Male hypogonadism is a clinical syndrome caused by androgen
More informationMale Hypogonadism. Types and causes of hypogonadism. What is male hypogonadism? Symptoms. Testosterone production. Patient Information.
Patient Information English 31 Male Hypogonadism The underlined terms are listed in the glossary. What is male hypogonadism? Male hypogonadism means the testicles do not produce enough of the male sex
More informationGUIDELINES ON MALE HYPOGONADISM
GUIDELINES ON MALE HYPOGONADISM (Text update March 2015) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch, M. Punab Introduction Male hypogonadism is a clinical syndrome caused by androgen
More informationLate onset Hypogonadism. Dr KhooSay Chuan Department of Urology Penang General Hospital
Late onset Hypogonadism Dr KhooSay Chuan Department of Urology Penang General Hospital Late onset hypogonadism(loh) Definition LOH age associated testoteronedeficiency syndrome (TDS) Male menopause, andropause,
More informationTestosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline
CLINICAL PRACTICE GUIDELINE Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline Shalender Bhasin, 1 Juan P. Brito, 2 Glenn R. Cunningham, 3 Frances J. Hayes,
More informationISSM QUICK REFERENCE GUIDE ON TESTOSTERONE DEFICIENCY FOR MEN
International Society for Sexual Medicine - www.issm.info ISSM QUICK REFERENCE GUIDE ON TESTOSTERONE DEFICIENCY FOR MEN Version: September 2015 What is testosterone deficiency? Testosterone deficiency
More informationGA KS KY LA MD NJ NV NY TN TX WA Applicable X X N/A N/A X N/A X X X X X X N/A N/A NA *FHK- Florida Healthy Kids. Androgens
Androgens Override(s) Prior Authorization Quantity Limit Approval Duration Varies upon diagnosis Medication Strengths Quantity Limit Comments Generic Androgel 1% (2.5 g) packet 2 packets per day (testosterone
More informationANDROGEN DEFICIENCY/MALE HYPOGONADISM
Medical Information to Support the Decisions of TUE Committees 1. Medical Condition Hypogonadism in men is a clinical syndrome that results from failure of the testes to produce physiological levels of
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
TESTOSTERONE REPLACEMENT THERAPY: ANDRODERM transdermal patch ANDROGEL pump transdermal gel and transdermal gel AXIRON transdermal solution FORTESTA transdermal gel NATESTO nasal gel STRIANT buccal mucoadhesive
More informationTestosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline
SPECIAL FEATURE Clinical Practice Guideline Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline Shalender Bhasin, Glenn R. Cunningham, Frances
More informationANDROGEN DEFICIENCY/MALE HYPOGONADISM
ANDROGEN DEFICIENCY/MALE HYPOGONADISM 1. Medical Condition Hypogonadism in men is a clinical syndrome that results from failure of the testes to produce physiological levels of testosterone (androgen deficiency)
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Acquired hypogonadism, prevalence of, 165 167 primary, 165 secondary, 167 Adipose tissue, as an organ, 240 241 Adrenal hyperplasia, congenital,
More informationin Primary Care (Part 2) Jonathan R. Anolik, MD, FACP, FACE Lewis Katz School of Medicine at Temple University
Common Endocrine Problems Seen in Primary Care (Part 2) Lecture #34 Jonathan R. Anolik, MD, FACP, FACE Lewis Katz School of Medicine at Temple University None Conflict of Interest Topics to be Covered
More informationBIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE
Authoriser: Moya O Doherty Page 1 of 7 BIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE The purpose of this protocol is to describe common tests used for the investigation
More informationPrior Authorization Criteria Update: Androgens, Topical and Parenteral
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationLaboratory Investigation of Male Gonadal Function. Dr N Oosthuizen Dept of Chemical Pathology UP 2010
Laboratory Investigation of Male Gonadal Function Dr N Oosthuizen Dept of Chemical Pathology UP 2010 1 Figure 1. Hypothalamic-pituitary pituitary-testicular testicular axis 2 Testosterone (T) measurement
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
TESTOSTERONE REPLACEMENT THERAPY: ANDRODERM transdermal patch ANDROGEL pump transdermal gel and transdermal gel ANDROID (methyltestosterone) oral capsule ANDROXY (fluoxymesterone) oral tablet AXIRON transdermal
More informationCorporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency
Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testosterone_pellet_implantation_for_androgen_deficiency
More informationWhat Is the Low T Syndrome? Is Testosterone Supplementation Safe?
What Is the Low T Syndrome? Is Testosterone Supplementation Safe? UCSF Osher Mini Medical School March 7, 2018 Dolores Shoback, MD Staff Physician SF-VAMC Professor of Medicine, UCSF No disclosures or
More informationDisclosures. Learning Objectives. Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease. None
Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease Micol S. Rothman, MD Associate Professor of Medicine Endocrinology, Diabetes and Metabolism Clinical Director Metabolic Bone
More informationTestosterone Injection and Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: December 8, 2017 Testosterone
More informationAndrogens. Medication Strengths Quantity Limit Comments Androderm (testosterone patch) 1% pump 2 pump bottles per Non-Preferred
Market DC Androgens Override(s) Prior Authorization Quantity Limit Approval Duration Varies upon diagnosis Medication Strengths Quantity Limit Comments Androderm (testosterone patch) AndroGel (testosterone
More informationTESTOSTERONE DEFINITION
DEFINITION A hormone that is a hydroxyl steroid ketone (C19H28O2) produced especially by the testes or made synthetically and that is responsible for inducing and maintaining male secondary sex characteristics.
More informationAndroderm patch, AndroGel packets and pump, Axiron solution, First- Testosterone, First-Testosterone MC, Fortesta gel, Testim gel, Vogelxo
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.31 Subject: Testosterone Topical Page: 1 of 9 Last Review Date: September 23, 2016 Testosterone topical
More informationTestosterone Injection / Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Testosterone Injection / Implant Page: 1 of 9 Last Review Date: December 5, 2014 Testosterone
More informationANDROGEN DEFICIENCY Update on Evaluation and Management
ANDROGEN DEFICIENCY Update on Evaluation and Management Kristen Gill Hairston, MD, MPH Associate Professor of Internal Medicine Section of Endocrinology and Metabolism Wake Forest University School of
More informationBasics of Male Libido: Dysfunction & Treatment. Ripu Hundal MD FACE First State Endocrinology Newark, DE
Basics of Male Libido: Dysfunction & Treatment Ripu Hundal MD FACE First State Endocrinology Newark, DE Sexual Hormones Steroid hormones Commonly referred to as male sex hormones and female sex hormones,
More informationTestosterone Injection and Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: March 17, 2017 Testosterone
More informationTestosterone Injection and Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: November 30, 2018 Testosterone
More informationTestosterone Therapy in Adult Men with Androgen Deficiency Syndromes:
The Endocrine Society s CLINICAL GUIDELINES Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline Authors: Shalender Bhasin, Glenn R. Cunningham,
More informationTestosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.32 Subject: Testosterone Oral Buccal Nasal Page: 1 of 10 Last Review Date: March 17, 2017 Testosterone Oral Buccal Nasal Description
More informationHormone Balance - Female Report SAMPLE. result graph based on Luteal Phase. result graph based on Luteal Phase
Patient Name: Patient DOB: Gender: Physician: Test Hormone Balance - Female Report SAMPLE Grote, Mary Jane Batch Number: B6437 2/16/1954 Accession Number: N52281 F Date Received: 2/3/2015 Any Lab Test
More informationTestosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.32 Subject: Testosterone Oral Buccal Nasal Page: 1 of 10 Last Review Date: June 24, 2016 Testosterone Oral Buccal Nasal Description
More informationLow Testosterone Consultation Information
T Low Testosterone Consultation Information www.urologyaustin.com Andropause or Male Menopause This syndrome has been nicknamed ADAM, which stands for androgen deficiency of the aging male. It differs
More informationClinical evaluation of infertility
Clinical evaluation of infertility DR. FARIBA KHANIPOUYANI OBSTETRICIAN & GYNECOLOGIST PRENATOLOGIST Definition: inability to achieve conception despite one year of frequent unprotected intercourse. Male
More informationClinical Policy: Testosterone Pellet (Testopel) Reference Number: CP.CPA.## [Pre-P&T approval] Effective Date:
Clinical Policy: (Testopel) Reference Number: CP.CPA.## [Pre-P&T approval] Effective Date: 07.25.17 Last Review Date: 11.17 Line of Business: Commercial Coding Implications Revision Log See Important Reminder
More informationTestosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.32 Subject: Testosterone Oral Buccal Nasal Page: 1 of 10 Last Review Date: November 30, 2018 Testosterone Oral Buccal Nasal
More informationHow to treat: TRT modalities and formulations
How to treat: TRT modalities and formulations Paul PIETTE, PharmD Senior Research Fellow Clinique Antoine Depage - Belgium ppiette@besins-healthcare.com Bruges 2014, May 15 th Testosterone-replacement
More informationEndocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh
Endocrine Update 2016 Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Disclosure of Financial Relationships Mary Korytkowski MD Honoraria British Medical Journal Diabetes Research
More informationIOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road 5)
IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road 5) 974-3131 -866-626-0216 Brett Faine, Pharm.D. Larry Ambroson, R.Ph. Brian Couse, M.D. Date: February 10, 2015 Mark Graber, M.D., FACEP,
More informationConsent for Testosterone Therapy-Men Revised 4/10/18
Consent for Testosterone Therapy in Men You have been diagnosed with or have an increased risk of having a hormone deficiency and your provider has recommended treatment with bio-identical hormone replacement
More informationOver the past decade, androgen replacement
J. Andrew Hoover, MD; Jeffrey T. Kirchner, DO, FAAFP Department of Family and Community Medicine, Lancaster General Hospital, Pa jhoover4@lghealth.org The authors reported no potential conflict of interest
More informationTUE Application for Testosterone Physician Worksheet
TUE Application for Testosterone Physician Worksheet Attention Physicians - USADA will not process Therapeutic Use Exemptions (TUE) for the use of testosterone unless all of the requirements for documentation
More informationImplantable Hormone Pellets
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationHYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY)
HYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY) DEFECT OF THE REPRODUCTIVE SYSTEM THAT RESULTS IN LACK OF FUNCTION OF THE GONADS (Wikipedia) REDUCTION
More informationTUE Physician Guidelines Medical Information to Support the Decisions of TUE Committees MALE HYPOGONADISM MALE HYPOGONADISM
1. Medical Condition Hypogonadism in men is a clinical syndrome that results from failure of the testes to produce physiological levels of testosterone (testosterone deficiency) and in some instances normal
More information43 year old man with low libido. Katie Stanley, MD August 16, 2012
43 year old man with low libido Katie Stanley, MD August 16, 2012 HPI 43 yo M with history of heroin addiction on methadone maintenance Reported low libido to PCP PCP checked testosterone and found to
More informationTestosterone (cypionate, enanthate, and propionate) powder, Fluoxymesterone powder, Methyltestosterone powder
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.37 Subject: Testosterone Powder Page: 1 of 12 Last Review Date: November 30, 2018 Testosterone powder
More informationManaging Testosterone Deficiency: A Practical Guide. John Grantmyre MD Professor of Urology Dalhousie University
Managing Testosterone Deficiency: A Practical Guide John Grantmyre MD Professor of Urology Dalhousie University 1 2 Case Study #1 A 59-Year-Old Man with Erectile Dysfunction 3 Case History Robert is a
More informationTestosterone (cypionate, enanthate, and propionate) powder, Fluoxymesterone powder, Methyltestosterone powder
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.37 Subject: Testosterone Powder Page: 1 of 11 Last Review Date: September 18, 2015 Testosterone powder
More informationDiagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes
Diagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes Adrian Dobs, M.D., M.H.S. Professor of Medicine and Oncology The Johns Hopkins University School of Medicine
More informationMechanism of hyperprolactinemia
Hyperprolactinemia Mechanism of hyperprolactinemia Causes of hyperprolactinemia Hormone-producing pituitary tumors Prolactinoma Acromegaly Hypothalamic/pituitary stalk lesion Tumors, cysts (craniopharyngeoma,
More information5/7/2013. Patrick Nolan, DO, FACE
Patrick Nolan, DO, FACE Patient: T.W. 83 year old male 9/18/2012 AM sudden onset of Vertigo ER visit Had MRI, some labs Home on Zofran and medicines Complete resolution of sx after 2 days MRI chronic sinus
More informationPoint-Counterpoint: Late Onset Hypogonadism (LOH)
Point-Counterpoint: Late Onset Hypogonadism (LOH) We are Under-diagnosing and Treating Men with LOH LOH is a Non-existent Disease ~ Robert E. Donohue, MD Late Onset Hypogonadism LOH: underdx. & undertx
More informationAromatase Inhibitors in Male Infertility:
Aromatase Inhibitors in Male Infertility: The hype of hypogonadism? BEATRIZ UGALDE, PHARM.D. H-E-B/UNIVERSITY OF TEXAS COMMUNITY PHARMACY PGY1 03 NOVEMBER 2017 PHARMACOTHERAPY ROUNDS Disclosures No conflicts
More informationDidactic Series. Hypogonadism and HIV. Daniel Lee, MD UCSD Medical Center, Owen Clinic July 28, 2016
Didactic Series Hypogonadism and HIV Daniel Lee, MD UCSD Medical Center, Owen Clinic July 28, 2016 This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department
More informationMale New Patient Package
Male New Patient Package The contents of this package are your first step to restore your vitality. Please take time to read this carefully and answer all the questions as completely as possible. Thank
More informationMale Patient Questionnaire & History
Male Patient Questionnaire & History Name: Today s Date: (Last) (First) (Middle) Date of Birth: Age: Weight: Occupation: Home Address: City: State: Zip: E-Mail Address: May we contact you via E-Mail? (
More informationReproductive Health and Pituitary Disease
Reproductive Health and Pituitary Disease Janet F. McLaren, MD Assistant Professor Division of Reproductive Endocrinology and Infertility Department of Obstetrics and Gynecology jmclaren@uabmc.edu Objectives
More informationMore than meets the eye
More than meets the eye Ana Paula Abreu, MD, PhD American Association of Clinical Endocrinologists New England Chapter Annual Meeting September 8, 2018 Disclosures No conflict of interest or significant
More informationProf Dato Dr TAN Hui Meng University of Malaya, Kuala Lumpur University of Pennsylvania, USA
Prof Dato Dr TAN Hui Meng University of Malaya, Kuala Lumpur University of Pennsylvania, USA Prevailing context Increase number of men who are potential candidates for Testosterone Replacement Therapy
More informationMale History, Clinical Examination and Testing
Male History, Clinical Examination and Testing Dirk Vanderschueren, MD, PhD Case Jan is 29 years old and consults for 1 year primary subfertility partner 28 years old and normal gynaecological investigation
More information66 M with erectile dysfunction and abnormal labs RAJESH JAIN ENDORAMA 10/29/2015
66 M with erectile dysfunction and abnormal labs RAJESH JAIN ENDORAMA 10/29/2015 HPI 66 M presenting as a referral for erectile dysfunction and abnormal labs Has been seeing a facility specializing in
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Pellet (Testopel) Reference Number: CP.PHAR.354 Effective Date: 08.01.17 Last Review Date: 11.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the
More informationLate Onset Hypogonadism. Toh Charng Chee Hospital Selayang
Late Onset Hypogonadism Toh Charng Chee Hospital Selayang Introduction Although suppressed serum testosterone (T) is common in ageing men, only a small proportion of them develop the genuine syndrome of
More informationHypogonadism in Men. CME Away India & Sri Lanka March 23 - April 7, 2018
Hypogonadism in Men CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright 2017
More informationInitials:.. Number of patient in the registry:... Date of visit:.. Gender (genetic): female / male
1. Patient personal details Institute code: Physician code: Initials:.. Number of patient in the registry:... Date of visit:.. Gender (genetic): female / male 2. Changes in acromegaly-specific medical
More informationBoard Review with The Chiefs. October 17, 2016 October 23, 2016
Board Review with The Chiefs October 17, 2016 October 23, 2016 Overview Registration Exam Details Test Day Details Study Resources Study Strategies Women s Health Men s Health What to Expect: Exam Registration
More informationTestosterone Therapy in Men An update
Testosterone Therapy in Men An update SANDEEP DHINDSA Associate Professor of Medicine Director, Division of Endocrinology and Metabolism, Saint Louis University, St. Louis, MO Presenter Disclosure None
More informationINFORMED CONSENT FOR FEMINIZING HORMONE THERAPY
INFORMED CONSENT FOR FEMINIZING HORMONE THERAPY The use of hormone therapy for gender transition/affirmation is based on many years of experience treating trans persons. Research on hormone therapy is
More informationHormonal Control of Human Reproduction
Hormonal Control of Human Reproduction Bởi: OpenStaxCollege The human male and female reproductive cycles are controlled by the interaction of hormones from the hypothalamus and anterior pituitary with
More informationProf. Dr. Michael Zitzmann Internal Medicine Endocrinology, Diabetology, Andrology University of Muenster, Germany
Induction of fertility in hypogonadal men Prof. Dr. Michael Zitzmann Internal Medicine Endocrinology, Diabetology, Andrology University of Muenster, Germany Induction of fertility in hypogonadal men Prof.
More informationTransgender Medicine: Essentials for the Primary Care Provider BENJAMIN J. BOH, DO, MS
Transgender Medicine: Essentials for the Primary Care Provider BENJAMIN J. BOH, DO, MS ASSISTANT PROFESSOR OF MEDICINE SECTION OF ENDOCRINOLOGY GEISEL SCHOOL OF MEDICINE AT DARTMOUTH Disclosure I will
More informationAn Update on Men s Health and Sexual Function
An Update on Men s Health and Sexual Function Lawrence Jenkins, MD, MBA Assistant Professor Clinical Department of Urology The Ohio State University Wexner Medical Center Outline Testosterone Deficiency
More informationSexual dysfunction of chronic kidney disease. Razieh salehian.md psychiatrist
Sexual dysfunction of chronic kidney disease Razieh salehian.md psychiatrist Disturbances in sexual function are a common feature of chronic renal failure. Sexual dysfunction is inversely associated with
More informationHIGHLIGHTS. From Testosterone Update Disease State Theater. American Urological Association and Endocrine Society Annual Meetings
HIGHLIGHTS From Testosterone Update Disease State Theater Presentations held at the 2008 American Urological Association and Endocrine Society Annual Meetings Jointly sponsored by the Annenberg Center
More informationASPEN MOUNTAIN MEDICAL CENTER. Lab Health Fair
ASPEN MOUNTAIN MEDICAL CENTER Lab Health Fair GENERAL HEALTH PANEL: CMP CMP The Comprehensive Metabolic Panel is used as a broad screening tool to evaluate organ function and check for conditions such
More informationA dro r gen e R e R p e lac a e c m e e m n e t t T her e a r p a y Androgen Replacement Therapy in the Aging O j b ecti t ve v s Male
Androgen Replacement Therapy in the Aging Male Thomas J. Walsh, MD, MS Department of Urology University of California, San Francisco Objectives 1. List 3 effects of androgens on normal male physiology.
More informationPRISM Bruges June Herman Leliefeld Urologist. The Netherlands
PRISM Bruges 25-26 June 2015 Herman Leliefeld Urologist The Netherlands Guidelines EAU 2015: a rich source of Knowledge! Epidemiology/ Aetiology / Pathology Diagnostic evaluation Disease management Follow-Up
More informationMen Getting Older Will Testosterone Keep Him Young?
Men Getting Older Will Testosterone Keep Him Young? Alvin M. Matsumoto, M.D. Associate Director, GRECC V.A. Puget Sound Health Care System Professor, Department of Medicine Division of Gerontology and
More informationStelios Mantis, MD DuPage Medical Group Pediatric Endocrinology
Stelios Mantis, MD DuPage Medical Group Pediatric Endocrinology 4 11 13 Initial Presentation Pt initially presented to pediatrician for school physical in fall 2012. Pt was found to be overweight (BMI:
More informationHormone Replacement Therapy For Men Consultation Information
Hormone Replacement Therapy For Men Consultation Information www.urologyaustin.com Biological Aging and Hormones As we age, a natural degeneration and aging of organs causes the levels of our hormones
More informationState of California, California Health and Human Services Agency, Department of Managed Health Care 2013:
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
More informationTEST REPORT # SB. Patient Name: Comprehensive Male Profile I Patient Phone Number: TEST NAME RESULTS 08/12/18 RANGE
TEST REPORT Ordering Provider: David Getuwell, MD 8605 SW Creekside Place Beaverton, OR 97008 Phone: 503-466-2445 Fax: 503-466-1636 Samples Received 08/15/2018 Report Date 08/20/2018 Samples Collected
More informationOverview of Reproductive Endocrinology
Overview of Reproductive Endocrinology I have no conflicts of interest to report. Maria Yialamas, MD Female Hypothalamic--Gonadal Axis 15 4 Hormone Secretion in the Normal Menstrual Cycle LH FSH E2, Progesterone,
More informationAQUA Registry 2019 Non-QPP Measure Specifications. Denominator Exceptions. IPSS<8 None None Yes Patient Reported Outcome (PRO)
AQUA12 Benign Prostate Hyperplasia: IPSS improvement after diagnosis with NEW diagnosis of clinically significant BPH who had IPSS (international prostate symptoms score) or AUASS (American urological
More informationTestosterone Therapy and the Prostate. Frans M.J. Debruyne Professor of Urology The Netherlands
Testosterone Therapy and the Prostate Frans M.J. Debruyne Professor of Urology The Netherlands TRT- Risks Prostate ( Cancer, BPH )? Cardiac? Lipids? Polycythemia Sleep apnea Gynecomastia Edema Testosterone
More informationHormone Therapy Overview for the Behavioral Health Provider. Julie Thompson, PA Fenway Health
Hormone Therapy Overview for the Behavioral Health Provider Julie Thompson, PA Fenway Health Continuing Medical Education Disclosure Program Faculty: Julie Thompson, PA Current Position: Physician s Assistant,
More information